Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperitone SCHEMBL111913 | 0.78 | TLR4 (0.40) | TLR4 | |
| (-)-Piperitone SCHEMBL3508682 | 0.78 | TLR4 (0.40) | TLR4 | |
| (-)-Piperitone SCHEMBL1248697 | 0.78 | TLR4 (0.40) | TLR4 | |
| SCHEMBL20047225 | 0.76 | TLR4 (0.34) | TLR4 | |
| SCHEMBL19287949 | 0.75 | TLR4 (0.32) | TLR4 | |
| SCHEMBL20133226 | 0.74 | CA1 (0.36) | TLR4 | |
| SCHEMBL15418676 | 0.72 | USP2 (0.33) | — | |
| SCHEMBL14535145 | 0.71 | — | — | |
| SCHEMBL12646071 | 0.71 | — | — | |
| SCHEMBL31391968 | 0.70 | TAS2R46 (0.41) | TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-9981910-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2018-05-29 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | GALAPAGOS NV (BE) | 2018-04-12 | — | — | US | disclosed |
| US-20180099931-A1 | Substituted Pyrrolidines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099931-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | TLR4 1417/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | TLR4 4774/4885 |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | TLR4 1632/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | TLR4 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.